Employees: 81
Size Lexicon Pharmaceuticals (LXRX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $766M, the 2402nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $1.72 on 18 Nov 2026.
Performance Over six months the shares fell 22.2%, against -7.0% for the median peer and -2.2% for the United States market (cap-weighted) — 4th lowest of 19 in its peer set.
Growth Revenue fell 45.6% over the last twelve months (peer median +3.5%); the operating margin is -147.4% (peer median 12.0%).
Valuation It trades at 16.7× enterprise value to sales against a peer median of 2.5× (2nd most expensive of 18).
Capital Return on invested capital runs 121.9 points below its cost of capital (10.2% WACC).
Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $38.5M | $49.8M | $31.1M | $1.20M | $139,000 |
| Revenue growth | — | +60% | +2,481% | +766% | — |
| Gross profit | $37.7M | $48.9M | $29.9M | $565,000 | -$288,000 |
| EBITDA | -$56.4M | -$48.3M | -$184M | -$171M | -$100M |
| Net income | -$62.4M | -$50.3M | -$200M | -$177M | -$102M |
| Free cash flow | -$49.2M | -$67.9M | -$181M | -$162M | -$90.2M |
| Capital expenditure | $0 | $0 | $1.03M | $470,000 | $1.33M |
| Total debt | $59.5M | $62.2M | $106M | $106M | $55.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | LXRX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.9% | -6.5% | 4th highest of 19 |
| 6-month return | -22.2% | -7.0% | 4th lowest of 19 |
| Distance from 52-week high | -35.8% | -32.6% | 7th lowest of 19 |
| Revenue growth (TTM) | -45.6% | +3.5% | lowest of 19 |
| Operating margin | -147.4% | 12.0% | 2nd lowest of 19 |
| EV / Sales | 16.7× | 2.5× | 2nd most expensive of 18 |
| ROIC minus cost of capital | -121.9 pp | +1.9 pp | 2nd lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Lexicon Pharmaceuticals LXRX | United States | $766M | -22% | -46% | -147% | 16.7× | n/a | n/a |
| Katakura Industries 3001.T | Japan | $765M | +40% | -2% | 15% | 2.4× | 0.3% | +0.5% |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $771M | -7% | -13% | 4% | 0.9× | -3.8% | -0.8% |
| Guizhou Bailing Group Pharmaceutical 002424.SZ | China | $755M | -20% | -25% | 2% | 2.5× | 13.5% | -0.2% |
| Bliss GVS Pharma BLISSGVS.NS | India | $777M | +141% | +25% | 18% | 6.7× | 33.9% | +10.1% |
| Sichuan Neautus Traditional Chinese 2206.HK | Hong Kong | $779M | n/a | +7% | 8% | n/a | n/a | n/a |
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $752M | -7% | +8% | 10% | 5.3× | 9.4% | -1.4% |
| CARsgen Therapeutics 2171.HK | Hong Kong | $751M | -45% | +68% | -170% | 28.6× | n/a | n/a |
| Zhejiang Int'l 000411.SZ | China | $783M | -21% | +3% | 3% | 0.3× | n/a | n/a |
| Ardelyx ARDX | United States | $784M | -50% | +18% | -8% | 1.6× | n/a | n/a |
| Jinghua Pharmaceutical 002349.SZ | China | $785M | -8% | +2% | 20% | 3.1× | -2.5% | +2.6% |
| Zhuzhou Qianjin Pharmaceutical 600479.SS | China | $746M | -3% | +4% | 11% | 1.4× | -2.1% | 0.0% |
| Bambusa Therapeutics BBTX | United States | $791M | n/a | n/a | n/a | n/a | n/a | n/a |
| Ironwood Pharmaceuticals IRWD | United States | $791M | +22% | +18% | 63% | 2.6× | n/a | n/a |
| Knight Therapeutics GUD.TO | Canada | $792M | +41% | +36% | 6% | 1.8× | 6.6% | +17.7% |
| Hunan Jiudian Pharmaceutical 300705.SZ | China | $738M | -20% | -5% | 13% | 1.8× | -2.0% | +26.1% |
| Oric Pharmaceuticals ORIC | United States | $795M | -9% | n/a | n/a | n/a | n/a | n/a |
| Luye Pharma 2186.HK | Hong Kong | $736M | -32% | +3% | 18% | 1.1× | -11.8% | +1.9% |
| Sanofi India SANOFI.NS | India | $797M | 0% | -6% | 26% | 4.1× | 16.3% | -8.7% |
| Rigel Pharmaceuticals RIGL | United States | $801M | +48% | +2% | 26% | 2.5× | 1.5% | +22.1% |
| Bide Pharmatech 688073.SS | China | $801M | +10% | +10% | 19% | 3.1× | 13.9% | +27.7% |